EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Comparisons

How should procurement score suppliers and negotiate contracts?

Dose Diligence research deskSection 03 · Page 10 of 12Last updated 17 Nov 2026

Score only arrangements that pass the gates, and score the evidence as well as the proposal. The weights below are suggested starting values, not validated industry standards.

Commercial criterionSuggested weightEvidence to use
Fulfilment and exception performance25%Pilot data and comparable historical reports
Patient affordability across the expected mix20%Matched quotations, eligibility and continuing-price scenarios
Clinic-controlled total cost20%Fees, implementation, handling and commitment exposure
Workflow and reporting15%Demonstrated events, exports and operational ownership
Continuity and exit readiness15%Tested fallback and transition deliverables
Implementation burden5%Named owners, dependencies and realistic milestones

Use a separate evidence flag: verified, supplier-reported, not provided, or requires specialist review. Missing evidence is not automatically adverse evidence, but a critical unanswered question should block selection rather than receive an optimistic score.

Which contract protections differ by arrangement?

Contract topicClinic-stock purchasingDispensing or access-service arrangement
Money at riskInventory title, deposits, credit, minimum orders and returnabilityImplementation fees, service minimums, prepaid services and unreconciled patient transactions
Supply failureAllocation, backorders, partial deliveries and replacement sourcingPrescription acceptance, delayed checkout, fulfilment failures and rerouting support
Product integrityStorage responsibility, shipment acceptance and quarantineInvestigation, patient contact, replacement and clinical escalation
Regulatory changeStop-order rights and treatment of committed inventorySuspension of affected routes, release from minimums and transition assistance
ExitInventory disposition, transaction records and outstanding creditsExportable order history, open-case reconciliation and lawful prescription-transition support
Price changesNotice, quote validity and interaction with broader commitmentsProgramme-change notification, service-fee changes and patient communication responsibilities

These are negotiation requests, not assurances that every supplier will accept them. Seek counsel's review of remuneration, patient choice, data use, indemnities, liability limitations and the precise supply arrangement.

Explore the table row by row

A working view of the research

Fulfilment and exception performance

Suggested weight
25%
Evidence to use
Pilot data and comparable historical reports

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →